Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
